Survival Time and Molecular Subtypes of Breast Cancer after Radiotherapy in Thailand

Apichat Kongsiang¹, Vorachai Tangvoraphonkchai², Chananya Jirapornkul¹, Supannee Promthet¹*, Siriporn Kamsa-ard³, Krittika Suwanrungruang⁴

Abstract

Background: Breast cancer is an important cause of death among women. One way of classifying different forms of breast cancer is by molecular features, usually in terms of the four subtypes: luminal A, luminal B, HER2-enriched, and triple negative. Objectives: This study aimed to investigate the association between molecular subtypes and survival among breast cancer patients treated with radiotherapy. Materials and Methods: A retrospective cohort study was conducted. The subjects were 272 breast cancer patients who had received treatment in the radiotherapy unit at Srinagarind Hospital, Thailand, between 1 January, 1999, and 31 May, 2009. The end of the study was 1 June, 2014. Overall survival was defined as the time elapsing between initial registration at the radiotherapy unit and death or the end of the study. Survival curves were estimated by the Kaplan-Meier method, and a multivariate analysis was performed using Cox’s proportional hazard regression model. Results: The patient mean age was 47.5±10.4 at the time of diagnosis. Of the 272 patients, 146 (53.7%) were classified as luminal A, 12 (4.4%) as luminal B, 30 (11.0%) as HER2-enriched, and 84 (30.9%) as triple negative. The overall survival rates at 1, 3 and 5 years were 87.1%, 68.4% and 59.2%, respectively. According to molecular subtypes, HER2-enriched patients had the lowest 5-year survival rate (30.0 %, 95%CI: 15.02-46.55). The median follow-up time was 8.37 years. In the Cox model analysis a higher risk of death was found for patients with HER2-enriched (HR_adj=3.34, 95%CI:1.96-5.67), triple negative (HR_adj=2.17, 95%CI: 1.44-3.27), and stage IIb (HR_adj=2.20, 95%CI: 1.16-4.17) cancers. Conclusions: The worst survival rates were among patients classified as HER2-enriched, triple negative and at stage IIb. Early detection and an advanced treatment modality are needed to help these patients.

Keywords: Breast cancer - survival - molecular subtypes - radiotherapy

Asian Pac J Cancer Prev, 15 (23), 10505-10508

Introduction

Breast cancer is an important health problem worldwide. It is the most common cancer in women and still increasing. It is one of the five most common causes of death from cancer in women (Khuhaprema et al., 2012; Ferlay et al., 2013). For the female population worldwide, the incidence rate is 38.9 per 100,000, and the mortality rate is 13.0 per 100,000 (Ferlay et al., 2013). Breast cancer incidence among Thai women is 30.7 per 100,000 and the mortality rate is 10.8 per 100,000 (Vatanasapt et al., 1995; Khuhaprema et al., 2012; Wirasorn et al., 2014). Recently, it has been suggested that there are various biomarkers such as an estrogen receptor (ER), a progesterone receptor (PR) and HER2/neu (HER2) which can be detected by immunohistochemistry (Dedes et al., 2011). These biomarkers are prognostic indicators of the survival in breast cancer patients (Cheang et al., 2009; Phipps et al., 2010). Breast cancers can be classified into four groups in terms of the phenotype of the biomarkers: luminal A, luminal B, HER2-enriched and triple negative (Phipps et al., 2010; Park et al., 2012). For each subtype there are differences reported in response to treatment, risk factors, clinical presentation and histology, all of which contribute to differences in the overall prognosis of the disease (Dedes et al., 2011; Wong et al., 2011; Park et al., 2012).

In Thailand, there have been few studies about breast cancer survival and no study about survival after radiotherapy or in terms of biomarkers and molecular subtypes (Sriamporn et al., 1995; Suwanrungruang et al., 2011; Chuthapisithet al., 2012; Poum et al., 2012; Chuangsawanich et al., 2014). This study aimed to investigate the association between molecular subtypes and survival among breast cancer patients treated with radiotherapy. It is hoped that the findings will help in...
making recommendations for future improvements in the early diagnosis and treatment of invasive breast cancer.

Materials and Methods

A retrospective cohort study of 272 breast cancer patients was conducted. All the patients had received radiotherapy treatment in the radiotherapy unit at Srinagarind Hospital, Khon Kaen University, Thailand, between 1 January, 1999, and 31 May, 2009. The data were extracted from medical records and pathology reports, and the inclusion criteria were: 1) a histologically proven diagnosis of female primary invasive breast cancer based on the International Classification of Diseases for Oncology 3rd edition (sites C50.0-C50.9) (Fritz et al., 2000); 2) age between 18 and 80 years; 3) had received surgery, and 4) a complete set of data required for the study was available. The patients were followed up until death or the end of the study (1 June, 2014).

The independent variables were age at diagnosis, parity, presence/absence of HER2/neu, ER, PR, Ki-67, molecular subtypes, resection margin (negative or positive), size/extent of primary tumor, degree of involvement of regional lymph nodes, stage of disease, and histological type. The dependent variable was the survival time of patients with breast cancer. In order to calculate the survival time, the starting point was defined as the date of registration at the radiotherapy unit, and the follow-up period ended when a patient died or on completion of the study. Censored data were used for those still alive at the end of the study or lost to follow-up. The follow-up status of each patient was determined from the medical record and by linkage with the death registry of the national statistics database.

Immunohistochemistry was used to detect the biomarker phenotypes of ER, PR and HER2, and hierarchical clustering analysis was employed to classify the patients onto one of the four molecular subtypes: 1) luminal A (ER+/PR+/HER2-, ER+/PR-/HER2-, ER-/PR+/HER2-); 2) luminal B (ER+/PR+/HER2+, ER+/PR-/HER2+, ER-/PR+/HER2+); 3) HER2-enriched (ER-/PR-/HER2+) and 4) triple negative (ER-/PR+/HER2-) (Parise et al., 2009).

Descriptive statistics were used for an exploratory data analysis. Percentages were used to summarise categorical data, and means with standard deviations or medians with ranges were used for continuous data. The observed survival rates were calculated by the Kaplan-Meier method. Median survival times with 95% confidence intervals (CIs) and the log-rank test were used for comparisons between groups. The Cox proportional hazard regression model with backward elimination was used to assess associations between the various independent variables (covariates) and survival, and the adjusted hazard ratios were tested for significance using the partial likelihood test. The level of significance was set as p<0.05. All analyses were performed using STATA version 10.0 (StataCorp LP, 2007).

The research was approved by the Khon Kaen University Ethics Committee for Human Research (Reference no. HE571081).

Results

The analyses were based on all the 272 patients selected for inclusion in this study. Their mean age was 47.5±10.39 at the time of diagnosis, and 146 (53.7%) were classified as luminal A, 12 (4.4%) as luminal B, 30 (11.0%) as HER2-enriched and 84 (30.9%) as triple negative. Regarding cancer staging, stages IIIA and IIIB were the most common, and almost all (99.3%) were found to have the ductal carcinoma type of the disease (Table 1).

At the end of the study, there had been 123 deaths which represents a mortality rate of 9.13 per 100 person-years (95% CI: 7.65 -10.89), and the median survival time after radiotherapy was 8.37 years (95% CI: 6.96-9.78). The overall survival rates for 1, 3 and 5 years were 87.1% (95%CI: 82.54 -90.59), 68.4% (95%CI: 62.49-73.55) and 59.2% (95%CI: 53.09 -64.76), respectively (Figure 1). Regarding molecular subtypes, the 5-year survival rates were: luminal B=75.0% (95%CI: 40.84-91.17), luminal A=70.5 (95%CI: 62.40-77.22), triple negative=47.6%

Table 1. Demographic and Clinical Characteristics of Breast Cancer Patients after Radiotherapy (N=272)

| Variables                | No. | %   |
|-------------------------|-----|-----|
| Age (years)             |     |     |
| ≤ 45                    | 122 | 44.9|
| > 45                    | 150 | 55.1|
| Mean (SD)               | 47.5| (10.4)|
| Parity                  |     |     |
| 0                       | 63  | 23.2|
| 1                       | 27  | 9.9 |
| 2                       | 85  | 31.3|
| ≥ 3                     | 97  | 35.7|
| Median (min, max)       | 2 (0, 9)|     |
| Estrogen Receptor       |     |     |
| Negative                | 129 | 47.4|
| Positive                | 143 | 52.6|
| Progesterone Receptor   |     |     |
| Negative                | 190 | 69.9|
| Positive                | 82  | 30.1|
| HER-2/neu               |     |     |
| Negative                | 230 | 84.6|
| Positive                | 42  | 15.4|
| Ki-67                   |     |     |
| Negative                | 89  | 32.7|
| Positive                | 183 | 67.3|
| Molecular subtypes      |     |     |
| Luminal A               | 146 | 53.7|
| Luminal B               | 12  | 4.4 |
| HER2-enriched           | 30  | 11.0|
| Triple negative         | 84  | 30.9|
| Resection margin        |     |     |
| Yes                     | 189 | 69.5|
| No                      | 83  | 30.9|
| Primary tumor           |     |     |
| T1                      | 58  | 21.3|
| T2                      | 103 | 37.9|
| T3                      | 46  | 16.9|
| T4                      | 65  | 23.9|
| Regional lymph nodes    |     |     |
| N0                      | 115 | 42.3|
| N1                      | 107 | 39.3|
| N2                      | 46  | 16.9|
| N3                      | 4   | 1.5 |
| Stage of disease        |     |     |
| Stage I                 | 32  | 11.8|
| Stage II A              | 58  | 21.3|
| Stage II B              | 49  | 18.0|
| Stage III A             | 64  | 23.5|
| Stage III B             | 63  | 23.2|
| Stage III C             | 6   | 2.2 |
| Histological type       |     |     |
| Ductal carcinoma        | 270 | 99.3|
| Lobular carcinoma       | 2   | 0.7 |

*SD= Standard deviation
Figure 1. Kaplan–Meier Curve of Overall Survival of Breast Cancer Patients after Radiotherapy

Figure 2. Kaplan-Meier Curves of Survival for the Molecular Subtypes

Table 2. Multivariate Analyses of the Factors Associated with Overall Survival by Cox Proportional Hazard Model

| Factors          | Crude HR (95% CI) | Adjust HR * (95% CI) | p-value |
|------------------|-------------------|----------------------|---------|
| Molecular subtypes |                   |                      | <0.001  |
| Luminal A        | 1                 | 1                    |         |
| Luminal B        | 1.02 (0.40-2.59)  | 0.95 (0.37-2.45)     |         |
| Triple negative  | 2.14 (1.43-3.19)  | 2.17 (1.44-3.27)     |         |
| HER2-enriched    | 3.77 (2.27-6.26)  | 3.34 (1.96-5.67)     |         |
| Stage of disease |                   |                      | <0.001  |
| Stage I          | 1                 | 1                    |         |
| Stage IIA        | 0.62 (0.301-0.29) | 0.74 (0.35-1.56)     |         |
| Stage IIB        | 0.80 (0.39-1.66)  | 1.04 (0.50-2.16)     |         |
| Stage IIIA       | 1.35 (0.71-2.57)  | 1.33 (0.68-2.60)     |         |
| Stage IIIB       | 1.98 (1.06-3.70)  | 2.20 (1.16-4.17)     |         |
| Stage IIIC       | 2.07 (0.67-6.36)  | 2.61 (0.84-8.09)     |         |

*Adjusted for Ki-67, regional lymph nodes, primary tumor and resection margin; HR= Hazard ratio, CI= Confidence interval; p-value from partial likelihood ratio test

(95%CI: 36.65-57.79), and HER2-enriched=30.0% (95%CI: 15.02-46.55) (Figure 2).

In the Cox final model, statistically significant risks of death were found to be associated with HER2-enriched (HRadj=3.34, 95%CI: 1.96-5.67), triple negative (HRadj=2.17, 95%CI: 1.44-3.27), and stage IIIB (HRadj=2.20, 95%CI: 1.16-4.17) (Table 2).

Discussion

In this present study, we employed a retrospective cohort design, using data on breast cancer patients who had received radiotherapy at our local University Hospital over a 10 year period. The results showed that the median survival time was 8.37 years, and survival rates after receiving the radiotherapy at 1, 3 and 5 years were 87.1%, 68.4% and 59.2%, respectively. These rates are consistent with those of another study in Northeastern Thailand, which found that the survival rates at 1, 3 and 5 years were 83.3%, 59.9% and 42.9%, respectively (Poum et al., 2012). Outside Thailand, while our median survival rate is higher than the 5.7 years found by a study of breast cancer patients in Malaysia (Abdullah et al., 2013), our findings are lower than those reported in Iran. A study of breast cancer patients after receiving radiotherapy in Iran found that the survival rates at 1, 3 and 5 years were 96.0%, 86% and 81.0%, respectively (Ziae et al., 2013).

Our finding that breast cancer patients with triple negative and HER2-enriched had lower survival rates than patients with luminal A and B is in line with outcomes of study done in Italy. The Italian study reported that the survival of breast cancer patients with triple negative and HER2-enriched had lower survival rates than patients with other molecular subtypes (Minicozzi et al., 2013). Our findings are also supported by a study of breast cancer in black women, which found that triple negative and HER2-enriched patients had the lowest survival 5-year survival rates (Ihemelandu et al., 2008). Our findings and those of others indicate that different molecular subtypes are associated with different survival rates and that the rates are likely to be lowest in breast cancer patients with triple negative and HER2-enriched molecular subtypes. However, a study of breast cancer patients in California, USA, found that the 5-year survival of triple negative and HER2-enriched patients were 69.2% and 76.2% which are higher than our findings (Parise et al., 2009). This may due to differences in racial characteristics, treatment modality, and stage. In addition to providing information about prognosis molecular subtypes may also have implications for the choice of optimum treatment modality (Chae & Gonzalez-Angulo, 2014).

The present study found that breast cancer patients with stage IIIIB had a significantly higher risk of death. This is consistent with the findings of a study of African-American women with breast cancer (Ihemelandu et al., 2008), which reported that patients with stage III and IV cancers had a higher risk of death than patients with stage I and II malignancies (HR=2.33, 95%CI: 1.11-44.89).

Limitation of the study

The 272 patients included in this study were those for whom a complete set of data was available. The exclusion of those with incomplete data is potential source of bias. However, the characteristics of those excluded due to incomplete data were similar to and not statistically different from those with complete data.

In conclusion, the overall survival at 1, 3, 5 years were $87.1\%$, $68.4\%$ and $59.2\%$. The worst survival rates were among the HER2-enriched and triple negative subtypes and those at stage IIIB. Early detection and an advanced treatment modality are needed to help these patients.

Acknowledgements

This research was supported by the Khon Kaen University Graduate Research Fund for Academic Year...
References

Abdullah NA, Wan Mahiyuddin WR, Muhammad NA, et al (2013). survival rate of breast cancer patients In Malaysia: a population-based study. *Asian Pac J Cancer Prev*, **14**, 4591-4.

Chae YK, Gonzales-Angulo AM (2014). Implications of functional proteomics in breast cancer. *The Oncologist*, **19**, 328-35.

Cheang MCU, Chia SK, Voduc D, et al (2009). Ki67 Index, HER2 status, and prognosis of patients with luminal B breast cancer. *J National Cancer Inst*, **101**, 736-50.

Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P, et al (2014). Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. *Asian Pac J Cancer Prev*, **15**, 1187-92.

Chuthapisith S, Permsapaya W, Warmissorn M, et al (2012). Breast cancer subtypes identified by the ER, PR and HER2 status in Thai women. *Asian Pac J Cancer Prev*, **13**, 459-62.

Dedes K, Wilkerson P, Reis-Filho J (2011). Immunohistochemistry and molecular biology of breast cancers: old and new prognostic factors. In ‘Breast Cancer, a Heterogeneous Disease Entity’, Eds Springer Netherlands, 119-48.

Engström MJ, Opdahl S, Hagen AI, et al (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Research and Treatment*, **140**, 463-73.

Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International agency for research on cancer.

Fritz A. G. (2000). International Classification of diseases for oncology: ICD-O-3, Geneva, Switzerland, World Health Organization.

Ihemelandu CU, Naab TJ, Mezghebe HM, et al (2008). Treatment and survival outcome for molecular breast cancer subtypes in black women. *Annals of Surgery*, **247**,465-9.

Jung H, Park Y, Kim M, et al (2014). Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology. *Tumor Biology*, 1-7.

Karimi A, Delphisheh A, Sayehmiri K, Saboori H, Rahimi E (2014). Predictive factors of survival time of breast cancer in kurdistan province of Iran between 2006-2014: A Cox Regression Approach. *Asian Pac J Cancer Prev*, **15**, 8483-8.

Khuhaprema T, Attasara P, Sriplung H, et al (2012). Cancer in Thailand VI 2004-2006, Bangkok, National Cancer Institute.

Minicozzi P, Bella F, Toss A, et al (2013). Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. *J Cancer Research Clinical Oncol*, **139**,1569-77.

Parise CA, Bauer KR, Brown MM, et al (2009). Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. *The Breast J*, **15**, 593-602.

Parise CA, Caggiano V (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. *J Cancer Epidemiology*, **2014**, 1-11.

Park S, Koo JS, Kim MS, et al (2012). Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. *Breast*, **21**, 50-7.

Petrelli F, Barni S (2012). Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. *Medical Oncology*, **29**, 2586-93.

Phipps A, Li C (2010). Breast cancer biology and clinical characteristics. In ‘Breast Cancer Epidemiology’, Eds Springer New York, 21-46.

Poum A, Kamsa-ard S, Promthet S (2012). Survival rates of breast cancer: a hospital-based study from northeast of Thailand. *Asian Pac J Cancer Prev*, **13**, 791-4.

Sriamporn S, Black R, Sankaranarayanan R,et al (1995). Cancer survival in Khon Kaen province, Thailand. *Int J Cancer*, **61**,296-300.

StataCorp LP (2007). Stata Release 10: User’s guide. College Station TX: Stata Press.

Suwanrungruang K, Vatanasapt P, Kamsa-Ard S, et al (2011). Cancer survival in Khon Kaen, Thailand, 1993-1997. *IARC SciPubl*, **162**, 211-6.

Vatanasapt V, Martin N, Sriplung H,et al (1995). Cancer incidence in Thailand 1988-1991. *Cancer Epidemiol, Biomarkers Prev*, **4**,475-483.

Wirasorn K, Suwanrungruang K, Wiangnon S, et al (2014). Numbers of new cases and trends of cancer 1993-2012: Srinagarind hospital based population, KhonKaen, North East Thailand. *Asian Pac J Cancer Prev*, **15**,8423-7.

Wong FY, Chin FK, Lee KA, Soong YL, Chua ET. (2011). Hormone receptors and HER2 status as surrogates for breast cancer molecular subtypes prognostic for disease control in node negative Asian patients treated with breast conservation therapy. *Ann Acad Med Singapore*, **40**,90-6.

Ziaezi JE SZ, Asvadi I, Dastgiri S, Pourzand A, Vaez J. (2013). Survival analysis of breast cancer patients in northwest Iran. *Asian Pac J Cancer Prev*, **14**,39-42.